Form 8-K · Current Report · Filed 2025-11-24
Agilent Technologies Announces Strong Q4 2025 Financial Results and FY26 Guidance
Agilent Technologies, Inc. reported strong financial results for the fourth quarter of fiscal year 2025, with revenue of $1.86 billion, GAAP net income of $434 million, and non-GAAP net income of $452 million. The company also provided full-year 2026 revenue guidance in the range of $7.3 billion to $7.4 billion, representing growth of 5% to 7% reported and up 4% to 6% on a core basis. Additionally, Agilent furnished its press release as Exhibit 99.1, which contains detailed financial information and outlook.
- Filer
- Agilent Technologies Inc. A · NYSE
- Filed
- Accession
- 0001090872-25-000070
- CIK
- 0001090872
- Signal
- High impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Results of Operations and Financial Condition
Financial Statements and Exhibits
Market reaction
Close before filing
$151.25
Next session
+3.9%
Since filing
-8.5%
Latest close
$138.37
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from A reporting the same item, with the next session's move:
About Agilent Technologies Inc.
Agilent Technologies Inc. is a global leader in the development and provision of life sciences, diagnostics, and applied chemical markets. Primarily focused on delivering superior analytical instruments, software, services, consumables, and reagents, the company plays a critical role in supporting the research needs of pharmaceutical, biotechnology, and government laboratories. Agilent's robust portfolio includes innovative solutions for genomics, proteomics, and metabolomics, aiding in critical areas such as disease research, food safety, and environmental analysis. Established in 1999 as a spin-off from Hewlett-Packard, the company leverages its heritage of technological innovation to enhance analytical capabilities for its clients. Agilent's significant contributions to health and safety applications underscore its importance in advancing scientific understanding and supporting public health initiatives worldwide.
Never miss another A filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.